Targeted diagnostics Nirmidas Biotech specializes in novel fluorescence detection platforms and pGOLD assays for immune response and neutralization antibodies, presenting opportunities to pilot or co-develop portable diagnostic systems and multiplexed tests with clinical labs, vaccine researchers, and point-of-care providers.

Expansion potential Recent product launches and partnerships, including DeepVision NIR-II/SWIR imaging and collaborations with camera manufacturers, indicate readiness for bundled imaging solutions and integrated assay-imaging workflows for research centers and preclinical facilities.

Early market entry With a seed-to-growth funding history and a focus on rapid deployment of IgG/IgM/IgA COVID-19 assays, there are sales opportunities in screening programs, population health initiatives, and serology testing services targeting public health agencies and biopharma clients.

High-precision tooling The company’s emphasis on high-sensitivity fluorescence, micro-liter sample requirements, and NIR-based detection suggests partnerships with contract research organizations and labs seeking turnkey, low-sample-volume diagnostic platforms and biomarker detection capabilities.

Strategic alliances Existing collaboration with Raptor Photonics for camera selection points to cross-sell opportunities with imaging hardware vendors and system integrators to create end-to-end diagnostic and research imaging solutions.